Introduction
Inspection readiness isn’t something you build in the weeks before a regulator arrives. It’s the condition your organisation is in every other day of the year.
For companies operating in or supplying to the EU market, that condition is shaped by a web of directives, regulations, and enforcement frameworks that have shifted considerably since 2022. The Clinical Trials Regulation (CTR) No. 536/2014 fully replaced the old Clinical Trials Directive in January 2022. GMP certificate extensions granted during the COVID-19 pandemic expired at the end of 2024, meaning the temporary regulatory flexibilities that many companies quietly relied on are now gone. And the EU-FDA Mutual Recognition Agreement (MRA) continues to extend, progressively reducing duplicated inspection work while raising the bar for what “equivalent” GMP capability actually means in practice.
This guide covers the key EU directives affecting inspection readiness, what inspectors are currently focused on, and what practical steps organisations can take to stay prepared, not just compliant on paper.
The Core Regulatory Framework
EU GMP and EudraLex Volume 4
The foundational document for pharmaceutical manufacturing in the EU is EudraLex Volume 4, the EU’s GMP guidelines. Any manufacturer of medicines intended for the EU market must comply with EU GMP regardless of where in the world they’re located. The European Medicines Agency coordinates inspections to verify compliance and plays a central role in harmonising GMP activities across member states.
From 2025, the temporary extension of GMP certificate validity that applied during the pandemic no longer applies. The GMP/GDP Inspectors Working Group, which had prolonged this extension through the end of 2024, took the decision in light of national competent authorities (NCAs) having resumed regular on-site inspections, alongside the use of other compliance-gathering methods such as distant assessments and international partner inspections.
The practical consequence: any organisation that had grown accustomed to operating under extended certificate validity now needs to meet standard timelines again, and NCAs are working through the backlog of inspections that accumulated during the pandemic period.
Clinical Trials Regulation (EU) No. 536/2014
On 31 January 2022, the EU Clinical Trials Regulation (CTR) No. 536/2014 replaced the Clinical Trials Directive No. 2001/20/EC, harmonising the processes for assessment and supervision of clinical trials throughout the EU.
For sponsors and CROs, the CTR introduced a centralised submission and authorisation process via the Clinical Trials Information System (CTIS). Member States must appoint inspectors to supervise compliance with the regulation and ensure those inspectors are adequately qualified and trained. Implementing Regulation (EU) 2017/556 sets out the detailed arrangements for good clinical practice inspection procedures under CTR 536/2014.
Both the EMA and national competent authorities are empowered to conduct GCP inspections under the CTR. Findings are documented within CTIS and may be subject to follow-up, suspension, or revocation of trial authorizations.
The EU-FDA Mutual Recognition Agreement
The EU-FDA MRA, which covers pharmaceutical GMP inspections for human medicines and veterinary products, has progressively expanded. On 30 May 2023, the US FDA confirmed that the national competent authorities of Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Greece, Hungary, Ireland, Luxembourg, Netherlands, Poland, Portugal, Slovenia and Spain have pharmaceutical GMP inspection capability, capacity and procedures equivalent to those of the US. On 26 September 2023, Sweden was added, and on 28 November 2023, Latvia was recognised.
For organisations operating across both jurisdictions, this mutual recognition matters practically: it reduces duplicate inspection burden, but it also means that a compliance failure visible to one regulator is increasingly visible to both.
What EU GMP Inspectors Are Currently Focused On
Pharmaceutical audits focus on specific critical areas that regulators use to assess overall GMP compliance and system robustness. These inspection points help FDA, EU, and WHO authorities determine whether a manufacturer consistently maintains control over quality, documentation, and production processes.
In 2024, more than 70% of critical GMP inspection findings were directly linked to failures in data integrity and weak pharmaceutical quality systems, highlighting a growing gap between regulatory expectations and real operational compliance.
Beyond data integrity, current EU GMP inspection focus areas include digital readiness (inspectors increasingly expect digital quality management systems and electronic batch records), supply chain oversight (expanded focus on vendor audits and raw material traceability), and risk-based targeting (high-risk facilities are prioritised for more frequent inspections).
The table below summarises the main differences between FDA and EU GMP inspection models, based on current enforcement frameworks:
| Area | FDA Model | EU GMP Model |
|---|---|---|
| Inspection frequency | Risk-based, no fixed cycle | At least every 3 years for EU-authorised manufacturers |
| Governing document | 21 CFR 210/211 | EudraLex Volume 4 |
| Primary authority | FDA | EMA + National Competent Authorities |
| Inspection findings system | FDA 483 / Warning Letters | Non-conformance reports via CTIS or NCA reports |
| Mutual recognition | MRA with EU (progressively expanding) | MRA with FDA (progressively expanding) |
| Data integrity focus | High | High (increasing) |
Practical Steps for Inspection Readiness
Conduct a gap analysis against current standards, not just the ones you know
Most inspection gaps don’t result from organisations ignoring GMP. They result from standards evolving faster than internal procedures do. EudraLex Volume 4 has been updated, CTR 536/2014 brought new requirements around CTIS submission and documentation, and the end of pandemic-era flexibilities means some previously tolerated practices are now findings.
A structured gap analysis should compare current SOPs and quality system documentation against the latest versions of applicable directives and guidance, not the versions your procedures were last updated against.
Get documentation inspection-ready before you're asked for it
Before any regulatory inspection, performing a thorough internal audit is crucial. That audit should evaluate documentation practices (ensuring all records are complete and accurate), quality systems effectiveness (reviewing procedures and checking for consistency in SOPs), and employee training and readiness (confirming that all staff are adequately trained and aware of GMP principles and inspection protocols). All documentation related to production, quality control, and staff training must be readily accessible for review during an inspection.
“Readily accessible” means having it at your fingertips when inspectors ask, not spending the first morning of an inspection locating files. The practical test: run a mock document retrieval exercise with someone unfamiliar with your filing system and see how quickly specific records can be found.
Treat the Trial Master File as a living document, not an archive
The EU Clinical Trial Regulation covers requirements for the retention of the Trial Master File (TMF/eTMF). The regulation came into effect in January 2022 for new trials and applies to all active clinical trials in the EU from January 2025.
Inspectors reviewing a TMF are not just checking whether the files exist. They’re checking whether they reflect what actually happened in the trial, in the correct version, documented at or close to the time of the event. An eTMF that is complete but months out of date on recent entries is a gap.
Run a mock inspection annually, not as a pre-inspection scramble
The organisations that perform best in GCP and GMP inspections tend to be the ones that run formal mock inspections on a regular schedule, not just when a real inspection is imminent. A mock inspection conducted six weeks before a real one is a remediation exercise. A mock inspection conducted eight months before a real one is an improvement cycle.
Continuous readiness requires embedding compliance into daily operations rather than treating it as a one-time project. Mock inspections, internal audits, and CAPA follow-through are the mechanisms that make that embedding real rather than aspirational.
Know your CTIS obligations if you run clinical trials in the EU
Successful implementation of CTR 536/2014 requires readiness in sponsor systems, SOP alignment, CTIS training, and real-time regulatory engagement. For organisations that transitioned from the old Directive framework, this means ensuring that CTIS submissions are current, that staff responsible for submissions have completed the relevant CTIS training modules, and that safety reporting timelines (including SUSAR reporting to EudraVigilance) are built into trial workflows rather than handled ad hoc.
Sponsors are advised to check the training modules for CTIS, the CTIS sponsor handbook with details on how to use CTIS, and the overview of structured data to be completed in CTIS.
Common Inspection Findings to Avoid
| Finding type | What it usually means in practice |
|---|---|
| Data integrity gaps | Manual records altered after the fact, or electronic systems without audit trails |
| Documentation version control failures | Obsolete SOPs in use, or current SOPs not signed/dated by staff |
| Training record gaps | Staff performing tasks for which no documented training record exists |
| CAPA ineffectiveness | Corrective actions closed without evidence of root cause resolution |
| Vendor oversight failures | Suppliers used without current approved supplier status or qualification documentation |
| TMF/eTMF incompleteness | Missing essential documents or entries significantly lagging the corresponding trial events |
Supporting Resources
- EudraLex Volume 4: EU Guidelines for Good Manufacturing Practice
- EU Clinical Trials Regulation 536/2014, official text
- Implementing Regulation (EU) 2017/556: GCP inspection procedures
- EMA Good Manufacturing Practice guidance
- EU-FDA Mutual Recognition Agreement: GMP
- CTIS training resources for sponsors
Sources
- European Commission, “Good Manufacturing and Distribution Practices”
- PharmaRegulatory.in, “EU GMP Inspection Preparation Explained”
- EMA, “Good Manufacturing Practice”
- Zamann Pharma, “GMP Regulations in 2026: FDA EU Inspection Checklist Guide”
- MasterControl, “FDA and EU Inspections: What to Know”
- Zamann Pharma, “Pharma Regulations in 2026: GMP Global Rules Guide”
- PharmaRegulatory.in, “Differences Between EU and FDA GMP Inspection Models”
- EUR-Lex, “High safety standards and streamlined procedures for EU clinical trials”
- European Commission, “Clinical Trials Regulation EU No 536/2014 in practice”
- Certara, “Clinical Trials Regulation EU No. 536/2014: The Impact on Annual Safety Reporting”
- Arkivum, “eTMF Retention Compliance: 6 Requirements”
- ClinicalStudies.in, “Comprehensive Overview of EU Clinical Trial Regulation CTR 536/2014”